StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.06−0.03 (-2.75%)

Close on Nov 18, 2026Market cap $282.13MP/E –Yield –

Autolus Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Autolus Therapeutics's price to sales ratio was 2.8× on Nov 11, 2026, against 7.3× a year earlier. Over the last 4 years it ranged from 2.8× to 462.7×, with a median of 183.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.8×−7.6
2025Dec 31, 202510.4×−154.5
2021Jan 29, 2021164.8×−35.7
2020Dec 31, 2020200.5×−95.6
2019Dec 31, 2019296.1×+64.0
2018Oct 31, 2018232.0×–

More Autolus Therapeutics figures

See a number that looks wrong?